Wip1 phosphatase activator QGC-8-52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells

By sjmartinez • January 10, 2025

Wu K, Ge XX, Duan XF, Li JQ, Wang K, Chen QH, Huang ZM, Zhang WY, Wu Y, Li Q. Wip1 phosphatase activator QGC-8-52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells. Drug Resist Updat. 2024 Dec 24;79:101196. doi: 10.1016/j.drup.2024.101196. Epub ahead of print. PMID: 39787991.

Tags: breast cancer, Dephosphorylation, FOXO3a, General Internal Medicine, King Drew Med Ctr, Post Doc, Publications, TRAIL, Wip1

A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study

Debonnaire P, Zwetsloot PP, Pfister R, Llàcer P, Cipriani A, Milani P, Bonderman D, Ohlmeier C, Evers T, Wyss R, Patorno E, Doshi R, Beisel[...]

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

Primary care physician characteristics and potentially inappropriate medications in older adults

Tatsuno Y, Sarkisian CA, Mafi JN, Kitajima K, Sato D, Tsugawa Y, Miyawaki A. Primary care physician characteristics and potentially inappropriate medications in older adults.[...]